Other Guidelines | Page 9 | European Cystic Fibrosis Society (ECFS)

Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020.

The role of the “PTM-CODE” in restoring F50del-CFTR functionality

Trends in the use of healthcare resources over time and the associated costs for people with cystic fibrosis?

Optimising equity of access: how should we allocate slots to the most competitive trials in Cystic Fibrosis (CF)?

Emergence and impact of oprD mutations in Pseudomonas aeruginosa strains in cystic fibrosis

Peripheral lung effect of elexacaftor/tezacaftor/ivacaftor in adult cystic fibrosis

Nasal high-flow therapy as an adjunct to exercise in patients with cystic fibrosis: A pilot feasibility trial

Vitamin D supplementation in patients with cystic fibrosis: A systematic review and meta-analysis

Meconium Ileus due to GUCY2C gene mutations in three unrelated South Indian families

MyCyFapp clinical trial sub-study on change in PERT and fat absorption

first
previous
…
5
6
7
8
9
10
11
12
13
…
next
last